| IMMUTEP LTD ADRS II/10 |
| USA |
| Gesundheit |
| US45257L1089 / A2H8YL |
| YP1A (Frankfurt) / IMMP (NASDAQ) |
| FRA:YP1A, ETR:YP1A, YP1A:GR, NASDAQ:IMMP |
| - |
| https://www.immutep.com/ |
|
Immutep Limited Sponsored ADR represents shares in Immutep Limited, an Australia-based late-stage biotechnology company specializing in Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases. The company's lea..
>Volltext.. |
| 40.54 Mio. EUR |
| -16.03 Mio. EUR |
| 2.32 Mio. EUR |
| -48.24 Mio. EUR |
| -46.93 Mio. EUR |
| -0.32 EUR |
| 0.7 Mio. EUR |
| 42.03 Mio. EUR |
| -34.02 Mio. EUR |
| 2.11 |
| - |
| -87.22% |
| - |
| - |
| - |
| - |
| IMMUTEP ADR, IMMUTEP |
| 06.04.26 |
|
||||
|
||||
|
||||
|